Cytokine Release Assay

Through Cytokine Release Assays (CRAs) scientists investigate the production of cytokines triggered by therapeutic proteins and small molecules in immune cells. The detection of compounds that trigger cytokine release syndrome (CRS) depends on this evaluation process. CRS stands out as a grave inflammatory reaction when substantial quantities of pro-inflammatory cytokines flood the bloodstream. The severe clinical consequences of these reactions include multi-organ failure and death which the TGN1412 clinical trial demonstrated when unexpected CRS occurred despite pre-existing safety assessments.